Furthermore, studies have shown that in melanoma, upregulating TYRO3 to limit tumor ferroptosis promotes resistance to α-PD-1/PD-L1 immune checkpoint inhibition [157], while enhancing tumor ferroptosis by targeting the Wnt/β-catenin-MITF pathway can improve the efficacy of anti-PD-1 immunotherapy [158]. The gene discussed is TYRO3; the disease is neoplasm.